Nationwide retrospective study of hepatitis B virological response and liver stiffness improvement in 465 patients on nucleos(t)ide analogue

Figure 1 Comparison of clinical outcomes in 465 chronic hepatitis B patients receiving 1^st generation (lamivudine or LAM, solid bar) vs 2^nd generation (tenofovir disoproxil fumarate or TDF, dotted bar) hepatitis B virus nucleos(t)ide analog therapy from baseline (pre-treatment) followed for up to 5 years. A: Hepatitis B virus DNA decline (log₁₀ IU/mL); B: Mean alanine aminotransferase (IU/mL) decline from baseline after starting lamivudine or tenofovir disoproxil fumarate. Mean with error bars representing standard deviation is plotted. LAM: Lamivudine; TDF: Tenofovir disoproxil fumarate; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.

Figure 2 Comparison of lamivudine vs tenofovir disoproxil fumarate on liver stiffness measurement over time. A: Liver stiffness measurement change from baseline (before treatment) and while on treatment; mean with error bars representing standard deviation is plotted; B and C: Comparison of fibrosis severity at baseline, 1-2 years, and 3-4 years post-treatment for lamivudine (B) and for tenofovir disoproxil fumarate (C). F0-F1 (yellow), F2-F3 (red), and F4 (purple). LSM: Liver stiffness measurement; LAM: Lamivudine; TDF: Tenofovir disoproxil fumarate.